Eurofins Strengthens Its Footprint in Food and Water Testing in The Netherlands with the Acquisition of Bureau de Wit
June 17 2016 - 12:30AM
Business Wire
Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), a world leader in
bioanalytical testing supporting the entire food production chain,
announces the acquisition of Bureau de Wit B.V. (“Bureau de Wit”),
one of the main laboratory service providers focused on food and
water safety testing for the food production, hotel and catering
sectors in The Netherlands.
Bureau de Wit operates a strategically-located laboratory in
Almere, and employs 64 staff, generating annual revenues in excess
of EUR 5m. The company provides food and water safety and hygiene
testing, with a strong reputation in the hotel and catering sectors
due to its innovative, client-friendly tools and state-of-the-art
client portals. Bureau de Wit’s existing competencies are entirely
complementary to Eurofins’ portfolio of services, which should
result in substantial cross-selling opportunities. Furthermore, its
laboratory’s central location provides a perfect fit with Eurofins’
existing geographic footprint in the country.
This acquisition further reinforces Eurofins’ leadership in the
Dutch food testing market and broadens its client base. In return,
Bureau de Wit will benefit from Eurofins’ industry-leading
laboratory network, including access to the Group’s comprehensive
analytical portfolio, as well as logistical infrastructure. The
existing Management of Bureau de Wit remains in place and will
continue to work on the growth of the Bureau de Wit business, now
as part of the successful Eurofins organisation.
Comment from Dr. Gilles Martin, Eurofins CEO: "This transaction
further consolidates our leading footprint to support the food
industry in The Netherlands. We look forward to giving Bureau de
Wit’s clients access to the capabilities of the Eurofins network to
support them in strengthening their quality and safety
programs.”
For more information about Eurofins, please visit
www.eurofins.com
Notes for the editor:Eurofins – a global leader in
bio-analysis
Eurofins Scientific believes it is the world leader in food,
environment and pharmaceutical products testing, as well as one of
the global market leaders in agroscience, genomics, discovery
pharmacology and central laboratory services. In addition, Eurofins
is one of the key emerging players in specialty clinical diagnostic
testing in Europe and the USA.
With over 23,000 staff in more than 225 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 validated
analytical methods for evaluating the safety, identity,
composition, authenticity, origin, traceability and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities and healthcare
practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:This press release contains
forward-looking statements and estimates that involve risks and
uncertainties. The forward-looking statements and estimates
contained herein represent the judgement of Eurofins Scientific’
management as of the date of this release. These forward-looking
statements are not guarantees for future performance, and the
forward-looking events discussed in this release may not occur.
Eurofins Scientific disclaims any intent or obligation to update
any of these forward-looking statements and estimates. All
statements and estimates are made based on the information
available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160616006189/en/
Investor RelationsEurofins Scientific GroupPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024